Lupin Limited reported a 37.4% year-on-year increase in net profit for the third quarter ended December 31, 2025, at ₹1,180.5 crore, compared with ₹858.9 crore in the corresponding quarter of the previous fiscal.
Revenue from operations rose 24.3% to ₹7,167.5 crore during the quarter, up from ₹5,767.8 crore a year earlier. The company invested ₹535.2 crore in research and development, accounting for 7.5% of sales.
Growth was driven primarily by strong performance in the United States, which contributes 44% of Lupin’s global sales. US revenues rose 54% year-on-year to ₹3,113.2 crore from ₹2,022.1 crore. India sales, representing 29% of global revenues, increased 5.6% to ₹2,038.7 crore.
Other developed markets, which account for 11% of global sales, recorded 10.8% growth at ₹812.1 crore. Emerging markets, contributing 13% of total sales, reported a 42.4% rise to ₹917 crore during the quarter.
The formulations business grew 29.1% to ₹6,881 crore. The active pharmaceutical ingredients (API) segment recorded growth of 26.4% compared to the same period last year.
As of December 31, 2025, the company had filed 431 cumulative ANDAs with the US regulator and received 341 approvals. It also holds 52 First-to-File (FTF) filings, including 22 exclusive FTF opportunities. Cumulative US Drug Master File (DMF) filings stood at 93.
Also Read